JYLAMVO

This brand name is authorized in Austria, Croatia, Estonia, Finland, Ireland, Lithuania, Poland, Romania, UK.

Active ingredients

The drug JYLAMVO contains one active pharmaceutical ingredient (API):

1	Methotrexate UNII YL5FZ2Y5U1 - METHOTREXATE
	Methotrexate (4-amino-10-methylfolic acid) is a folic acid antagonist which inhibits the reduction of folic acid and increase of tissue cells. Methotrexate enters the cell through an active transport mechanism of reduced folates. As a result of polyglutamation of methotrexate caused by the folylpolyglutamylate enzyme, the duration of the cytotoxic effect of the drug substance in the cell increases.
	Read more about Methotrexate

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JYLAMVO Oral solution	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BA01	Methotrexate	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BA Folic acid analogues
Discover more medicines within L01BA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1742587
FI	Lääkealan turvallisuus- ja kehittämiskeskus	185130
GB	Medicines & Healthcare Products Regulatory Agency	348711
LT	Valstybinė vaistų kontrolės tarnyba	1082615
PL	Rejestru Produktów Leczniczych	100386812
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65904001